Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Organogenesis Holdings Inc.NASDAQ: ORGO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns positive
Q1 FY2026 free cash flow was $17.98M, compared with -$23.56M a year earlier. Trailing-twelve-month free cash flow was $17.08M. Over 3 fiscal years it compounded at +39.4% a year.
Context
- Free cash flow amounted to 4.3% of revenue in FY2025, up 3.5 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near $17.98M or moves back toward the trailing-twelve-month quarterly average of $4.27M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (24.46M) USD
- Year-over-year change
- -685.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.46M) | -685.7% |
| FY2024 | 2024-12-31 | 4.18M | -36.3% |
| FY2023 | 2023-12-31 | 6.55M | +172.5% |
| FY2022 | 2022-12-31 | (9.04M) | -129.4% |
| FY2021 | 2021-12-31 | 30.76M | — |
Free Cash Flow vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +344.0% is the highest of 11, against a peer median of +13.8%.
- Free cash flow amounts to 3.3% of revenue for ORGO, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.01M USD | +25.5% | +34.0% | 360.7% | |
| LTM Mar 2026 | $135.4M USD | +43.4% | — | 20.0% | |
| LTM Mar 2026 | $53.29M USD | +20.5% | +12.7% | — | |
| LTM Mar 2026 | CA$52.75M CAD | +7.2% | — | 5.6% | |
| LTM Mar 2026 | $41.33M USD | +43.0% | -19.6% | 13.7% | |
| LTM Apr 2026 | $30.8M USD | -180.4% | — | 3.6% | |
| LTM Mar 2026 | $27.42M USD | -55.7% | +1.2% | 29.2% | |
| LTM Mar 2026 | $18.19M USD | -81.9% | -57.8% | 4.3% | |
| LTM Mar 2026 | $17.08M USD | +344.0% | +39.4% | 3.3% | |
| LTM Mar 2026 | $10.01M USD | -3.8% | +19.1% | — | |
| LTM Feb 2026 | $1.5M USD | +105.3% | +8.3% | 0.5% | |
| Peer median (excluding ORGO) | — | +13.8% | +8.3% | 9.7% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.